CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.cincor.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2022 | $22.00 | Overweight | Barclays |
| 11/29/2022 | Outperform → Perform | Oppenheimer | |
| 11/29/2022 | $60.00 → $22.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/28/2022 | $67.00 | Buy | Goldman |
| 8/22/2022 | $73.00 | Overweight | Piper Sandler |
| 2/1/2022 | Outperform | Evercore ISI | |
| 2/1/2022 | $30.00 | Outperform | Oppenheimer |
| 2/1/2022 | $27.00 | Overweight | Morgan Stanley |
| 2/1/2022 | $30.00 | Buy | Jefferies |
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
Barclays initiated coverage of CinCor Pharma with a rating of Overweight and set a new price target of $22.00
Oppenheimer downgraded CinCor Pharma from Outperform to Perform
Morgan Stanley downgraded CinCor Pharma from Overweight to Equal-Weight and set a new price target of $22.00 from $60.00 previously
Goldman initiated coverage of CinCor Pharma with a rating of Buy and set a new price target of $67.00
Piper Sandler initiated coverage of CinCor Pharma with a rating of Overweight and set a new price target of $73.00
Evercore ISI initiated coverage of CinCor Pharma with a rating of Outperform
Oppenheimer initiated coverage of CinCor Pharma with a rating of Outperform and set a new price target of $30.00
Morgan Stanley initiated coverage of CinCor Pharma with a rating of Overweight and set a new price target of $27.00
Jefferies initiated coverage of CinCor Pharma with a rating of Buy and set a new price target of $30.00
8-K - CinCor Pharma, Inc. (0001868734) (Filer)
25-NSE - CinCor Pharma, Inc. (0001868734) (Subject)
SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC TO-T/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC TO-T/A - CinCor Pharma, Inc. (0001868734) (Subject)
8-K - CinCor Pharma, Inc. (0001868734) (Filer)
SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC TO-T/A - CinCor Pharma, Inc. (0001868734) (Subject)